Medicament for treating gastrointestinal disorders
AssigneeGlaxo Group Limited
InventorAndrew Alexander McColm
Life of this patent
Estimating the term…
Abstract
The use is described of both (i) ranitidine bismuth citrate and (ii) one or more Helicobacter pylori-inhibiting antibiotics in treating or preventing gastrointestinal disorders. Pharmaceutical compositions containing both (i) and (ii) and methods for the preparation of pharmaceutical compositions containing (i) and (ii) are also described.
Claims28
A method for treating gastrointestinal disorders caused or mediated by H. pylori infections in humans or animals which comprises administering to a human or animal in need thereof an amount of ranitidine bismuth citrate effective against H. pylori in combination with a pharmaceutically acceptable carrier and an amount of amoxycillin effective against H. pylori in combination with a pharmaceutically acceptable carrier, said amoxycillin being administered in relative amounts such that the combination provides a greater than additive effect, said administration being concurrent or nonconcurrent.
A method for treating gastrointestinal disorders caused or mediated by H. pylori infections in humans or animals which comprises administering to a human or animal in need thereof an amount of ranitidine bismuth citrate effective against H. pylori in combination with a pharmaceutically acceptable carrier, an amount of amoxycillin effective against H. pylori in combination with a pharmaceutically acceptable carrier, and an amount of metronidazole effective against H. pylori in combination with a pharmaceutically acceptable carrier, said amoxycillin or said metronidazole being administered in a relative amount such that the combination with ranitidine bismuth citrate provides a greater than additive effect, said administration being concurrent or nonconcurrent.
A method for treating gastrointestinal disorders caused or mediated by H. pylori infections in humans or animals which comprises administering to a human or animal in need thereof an amount of ranitidine bismuth citrate effective against H. pylori in combination with a pharmaceutically acceptable carrier, and an amount of metronidazole effective against H. pylori in combination with a pharmaceutically acceptable carrier, said metronidazole being administered in a relative amount such that the combination with ranitidine bismuth citrate provides a greater than additive effect, said administration being concurrent or nonconcurrent.
Dependencies are inferred from the claim text.